Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04528004 · ClinicalTrials.gov registry record · Early Phase 1
Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure
A Early Phase 1 study of Heart Failure, Systolic and Metabolic Disturbance, sponsored by University of Washington.
- Active
- Registry status
- Early Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT04528004: Active Early Phase 1 study of Heart Failure, Systolic and Metabolic Disturbance, sponsored by University of Washington.
NCT04528004 is a Early Phase 1 study of Heart Failure, Systolic and Metabolic Disturbance that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 32 participants, below the 334-participant average among 13 other Heart Failure, Systolic trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04528004, a Early Phase 1 study of Heart Failure, Systolic and Metabolic Disturbance, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
Preliminary animal studies by ourselves and others suggest that the dietary supplement, nicotinamide riboside (NR), may improve cardiac function in heart failure (HF) by increasing cellular levels of its metabolite, nicotinamide adenine dinucleotide (NAD+, NADH). This Study will address a key gap in current knowledge by assessing the mechanisms through which raising blood and myocardial NAD+ levels in humans mediates changes in mitochondrial function, protein and epigenetic modifications, as well as inflammation. Human myocardium will be obtained after 4-14 days of oral NR supplementation from advanced heart failure patients undergoing elective left ventricular assist device (LVAD) implantation. Positive results would provide evidence to proceed with further studies of NR as a mitochondria-targeted metabolic therapy in heart failure.
Primary Outcome
Comparisons of whole blood NAD+ levels on the Day of LVAD Surgery in participants randomized to NR vs. placebo
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Nicotinamide riboside
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-09-26 |
| Est. Completion | 2025-07-31 |
| Phase | Early Phase 1 |
What the registry record for NCT04528004 still lists
NCT04528004 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 334-participant average among 13 other Heart Failure, Systolic trials with a reported enrollment target (90% lower).
The record links to 3 conditions, with Heart Failure, Systolic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04528004 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT04528004 about?
NCT04528004 is a clinical study titled "Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure". Preliminary animal studies by ourselves and others suggest that the dietary supplement, nicotinamide riboside (NR), may improve cardiac function in heart failure (HF) by increasing cellular levels of its metabolite, nicotinamide adenine dinucleotide (NAD+, NADH). This Study will address a key gap in...
What is the current status of trial NCT04528004?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 32 participants. The study started on 2020-09-26. Estimated completion is 2025-07-31.
What conditions does trial NCT04528004 study?
This clinical trial studies the following conditions: Heart Failure, Systolic, Metabolic Disturbance, Heart Failure NYHA Class IV.
What interventions are being tested in trial NCT04528004?
The interventions under investigation include: Placebo (OTHER), Nicotinamide riboside (DRUG).
Who is sponsoring clinical trial NCT04528004?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04528004 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure, Systolic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04528004's enrollment target sits among peer trials
32 10th of 13 higher than 4 of 13 other Heart Failure, Systolic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure, Systolic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
Pilot Study Lp299v Supplementation in Chronic Heart Failure
RECRUITING · NA
-
Paced Heart Rate Acceleration for Cardiac Conditioning
RECRUITING · NA
-
Associations Between the Microbiome, Skeletal Muscle Perfusion, and Fitness Status
RECRUITING
-
Evaluating Infrasonic Hemodynography
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI